Bettervits reports CBL-514 aims to kill fat cells rather than shrink them, with early human trial results it calls promising. Research is still ongoing.
Recap by typeshit. Post by @bettervits on Instagram.
A new GLP-1 described as stronger than current options is being tested in trials, and researchers lay out what people should understand about it.
A SURPASS-4 analysis at ASN Kidney Week 2026 found rapid kidney decline in 5% on tirzepatide versus 13% on insulin glargine, with the biggest gains in high protein groups.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
Researchers used AI to identify fungal peptides that taste salty or boost saltiness, aimed at cutting sodium in food. A food science find rather than a drug story.
He blames a 49ers game day for the uptick, reports no negative side effects so far, and says food noise keeps fading.
Vecchio calls the drugs a fresh start for her life, but Reuters notes the cost came in side effects, including gastrointestinal trouble.
Loading…